Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475155 | PMC |
| http://dx.doi.org/10.4266/acc.2021.01431 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CYP3A5 Polymorphisms Leading to Tacrolimus Toxicity Following an Adult Renal Transplant.
Saudi J Kidney Dis Transpl
May 2023
College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Tacrolimus is one of the calcineurin inhibitors used for maintaining immuno-suppression in thoracic and abdominal transplantations including heart, lung, liver, intestine, pancreas, and renal transplants. It has a narrow therapeutic window requiring therapeutic drug monitoring (TDM). Genetic polymorphism in the expression of cytochrome P3A5 enzyme plays a significant role in the bioavailability of tacrolimus in patients, leading to toxicity or rejection.
View Article and Find Full Text PDFTacrolimus toxicity-related chorea in an infant after liver transplantation.
Acute Crit Care
August 2022
Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Ankara, Türkiye.
Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission.
Transplant Cell Ther
July 2022
Department of Radiation Oncology, City of Hope, Duarte, California. Electronic address:
Graft-versus-host disease (GVHD) has remained the main cause of post-transplantation mortality and morbidity after allogeneic hematopoietic cell transplantation (alloHCT), adding significant economic burden and affecting quality of life. It would be desirable to reduce the rate of GVHD among patients in complete remission (CR) without increasing the risk of relapse. In this study, we have tested a novel conditioning regimen of total marrow and lymphoid irradiation (TMLI) at 2000 cGy, together with post-transplantation cyclophosphamide (PTCy) for patients with acute myeloid leukemia in first or second CR, to attenuate the risk of chronic GVHD by using PTCy, while using escalated targeted radiation conditioning before allografting to offset the possible increased risk of relapse.
View Article and Find Full Text PDFPhase I clinical trial of intra-bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation.
Stem Cells Transl Med
April 2021
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Mesenchymal stem cells (MSCs) have immunomodulatory properties and support hematopoiesis in the bone marrow (BM). To develop a new strategy to not only prevent graft-vs-host disease (GVHD) but also to enhance engraftment, a phase I trial of cord blood transplantation (CBT) combined with intra-BM injection of MSCs (MSC-CBT) was designed. Third-party BM-derived MSCs were injected intra-BM on the day of CBT.
View Article and Find Full Text PDFDevelopment of a Simple and Rapid Method to Measure the Free Fraction of Tacrolimus in Plasma Using Ultrafiltration and LC-MS/MS.
Ther Drug Monit
December 2016
Departments of *Clinical Pharmacy and †Intensive Care, University Medical Center Utrecht, Utrecht; and ‡Department of Clinical Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands.
Background: Tacrolimus is an immunosuppressant mainly used in the prophylaxis of solid organ transplant rejection. Therapeutic drug monitoring of tacrolimus is essential for avoiding toxicity related to overexposure and transplant rejection from underexposure. Previous studies suggest that unbound tacrolimus concentrations in the plasma may serve as a better predictor of tacrolimus-associated nephrotoxicity and neurotoxicity compared to tacrolimus concentration in whole blood.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!